KRAS G12C inhibitors in KRASG12C-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis - Takeaways - MDSpire

KRAS G12C inhibitors in KRASG12C-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis

  • By

  • Yici Yan

  • Leyi Zheng

  • Hongfei Wang

  • Leitao Sun

  • Xing Xu

  • July 10, 2026

  • 0 min

Share

  • 1

    The systematic review included 4 articles with 3 randomized controlled trials involving 949 participants treated with KRAS G12C inhibitors.

  • 2

    Progression-free survival was significantly better in the KRAS G12C inhibitor group compared to standard care (HR, 0.62; P < 0.001).

  • 3

    No significant difference in overall survival was observed between KRAS G12C inhibitors and standard care (HR, 0.93; P = 0.495).

  • 4

    Patients with PD-L1 expression levels <1% and 1%-49% showed improved progression-free survival with KRAS G12C inhibitors.

  • 5

    KRAS G12C inhibitors demonstrated a better safety profile, although diarrhea and rash were noted as adverse effects.

Original Source(s)

KRAS G12C inhibitors in KRASG12C-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis

  • by Yici Yan, Leyi Zheng, Hongfei Wang, Leitao Sun, Xing Xu

  • July 10, 2026

Related Content

Population-Level Outcomes for Screening Program Cancers in First Nations People in Ontario, Canada

Therapeutic assessment of Nerium oleander-derived exosome-like nanoparticles against triple-negative breast cancer: a preliminary in vitro and network pharmacology approach

Spatial transcriptomics reveals molecular differences associated with malignant transformation in oral epithelial dysplasia